Is NCT06056297 recruiting in Torrance, CA?

Yes, NCT06056297 is currently recruiting participants at its Torrance, CA location. This chronic neutropenia clinical trial is actively enrolling qualified participants.

How do I join the chronic neutropenia clinical trial in Torrance?

To join this clinical trial in Torrance, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Torrance clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Chronic Neutropenia Clinical Trial in Torrance, CA

About This Chronic Neutropenia Study in Torrance

The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections as assessed by demonstrating its clinical benefit and increasing levels of circulating neutrophils.

Sponsor: X4 Pharmaceuticals

Who Can Participate

Inclusion Criteria

Diagnosis of congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorder ≥6 months prior to the screening visit that is not attributable to medications, active or recent infections or malignancy.

Congenital Neutropenia, including but not limited to these classifications:

Isolated with a permanent (non-cyclic) presentation, for example, elastase, neutrophil expressed (ELANE), colony stimulating factor 3 receptor (CSF3R), C-X-C chemokine receptor 2 (CXCR2), Wiskott-Aldrich syndrome (WAS)

Associated with extra-hematologic manifestations, for example, Barth syndrome, Cohen syndrome, glucose-6-phosphatase catalytic subunit 3 (G6PC3), Kostmann disease

Associated with metabolic disorders, for example, glycogen storage disease 1b (GSD1b)

Shwachman-Diamond syndrome

Acquired Primary Neutropenia

Chronic idiopathic neutropenia

Primary autoimmune neutropenia. Other chronic neutropenia (CN) disorders that may be eligible for enrollment can be clarified and approved upon discussion with study Medical Monitor.

Have an ANC \<1000 cells/µL during screening (single ANC value from hematology) and confirmed trough mean ANC (mean value of multiple ANC measurements over 6 hours) at baseline visit, with no clinical evidence of systemic infection.

Prior history of recurrent and/or serious infections during the 12 months preceding the screening visit (that is, suffering sequelae of chronic neutropenia), as defined by having at least 2 infections in the last 12 months that meet the following criteria:

Infection requiring the use of antibiotics (intravenous \[IV\]/oral); OR

Infection requiring a visit to healthcare facility (including but not limited to emergency room visit, urgent care facility, primary care physician's office, or in-patient hospitalization); AND for all potential participants:

Infections considered by the Investigator to be likely related to the potential participant's CN disorder.

Participants who are on G-CSF or other active background therapy must have been receiving these therapies during the previous 12 months while continuing to suffer from infections, be on a stable dose and dosing schedule for ≥4 weeks prior to screening visit and remain on this dose and dosing schedule throughout the study (unless ANC \>10,000 cells/µL for ≥4 weeks).

Participants must be willing to keep their G-CSF or other background therapy doses/regimens stable (other than for safety reasons) for the duration of the study. Key

Exclusion Criteria

A diagnosis of secondary neutropenia including those due to:

Hypersplenism

Autoimmune disease, for example, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, graft-versus-host disease, thyroid disease

Nutritional deficiency, for example, vitamin B12, folic acid, copper, caloric malnutrition

Drug-induced cause, for example, chemotherapy, clozapine, antiretrovirals, antibiotics, monoclonal antibodies.

A diagnosis of any of the following:

Aplastic anemia

Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome

Certain CNs, including but not limited to these classifications are excluded:

Isolated with a cyclic presentation, for example, elastase, neutrophil expressed (ELANE)

Associated with immune dysregulation, for example, common variable immunodeficiency (CVID), autoimmune lymphoproliferative syndrome (ALPS), familial hemophagocytic lymphohistiocytosis, Chédiak-Higashi syndrome, GATA-binding protein 2 (GATA2) deficiency syndrome

Associated with bone marrow failure, for example, Fanconi anemia, Diamond-Blackfan anemia

Neutropenia associated with a Duffy-null phenotype (formerly known as benign ethnic neutropenia). However, a participant with an autosomal dominant pathogenic variant in a gene associated with CN on a Duffy-null background may be eligible for inclusion

A medical or personal condition that may potentially compromise the safety of the participant, may preclude the participant's successful completion of the clinical study, or could, in the opinion of the Investigator or the Medical Monitor, interfere with the objectives of the study.

Received more than 1 dose of mavorixafor in the past.

Received C-X-C chemokine receptor 4 (CXCR4) antagonist (other than mavorixafor) in the past 6 months.

Participants taking pegylated-G-CSF unless they have a diagnosis of congenital neutropenia confirmed at screening.

Participant is currently taking or has taken other investigational drug \<30 days prior to the screening visit or 5 half-lives, whichever is longer. Note: Other protocol-defined inclusion and exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Torrance?

Yes, this clinical trial (NCT06056297) has an active research site in Torrance, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Neutropenia Treatment Options in Torrance, CA

If you're searching for chronic neutropenia treatment options in Torrance, CA, this clinical trial (NCT06056297) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Torrance research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced chronic neutropenia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic neutropenia clinical trials near you to find additional studies recruiting in your area.

Chronic Neutropenia Clinical Trial in Torrance, CA

Expert Care in Torrance

IRB Approved

No-Cost Care

Apply for This Torrance Location

Why Participate?

Simple Process